Treating ankylosing spondylitis (AS) patients with Humira (adalimumab) or a potential biosimilar called IBI303 had comparable effects in…
Articles by Jose Marques Lopes PhD
Under-the-skin treatment with ixekizumab leads to early and sustained reductions in pain, fatigue, and inflammation, as well as significant improvements…
Stopping treatment with infliximab (brand names, Remsima, Remicade) can lead to relapses in people with ankylosing spondylitis (AS) who…
Treatment with Simponi (golimumab) reduced the incidence of a type of eye inflammation called acute anterior uveitis…
British Columbia is now reimbursing ankylosing spondylitis treatment Renflexis (infliximab-abda) under its public drug plan, according to Merck Canada.
The U.S. Food and Drug Administration approved a label update stating there is negligible to low transfer of UCB’s…
Treatment with Merck’s Simponi (golimumab) is now recommended for patients with severe non-radiographic axial spondyloarthritis (nr-axial SpA) in England and Wales.
The best site to determine bone loss in ankylosing spondylitis (AS) patients is the femoral neck, according to Swedish…
The European Union has expanded its approval of the rheumatic disease therapy UCB’s Cimzia t0 include women who are pregnant or…
Novartis recently initiated a Phase 3 clinical trial comparing its FDA-approved therapy Cosentyx (secukinumab) with GP2017 — an adalimumab biosimilar —…